EUCTR2010-020881-53-BE进行中（未招募）1 期
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject was randomized into study 20090072 and completed the week 12 evaluation.
- •Subject completed the week 12 evaluation in study 20090072 no more than 1 year prior to the planned first visit of AMG 827 in 20100008.
- •Subject or subject’s legally acceptable representative has provided informed consent.
- •Subject meets regional recommendations for immunizations, eg, United States Centers for Disease Control and Prevention recommendations for subjects enrolled in the United States.
- •For subjects with = 3 months between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008: If testing is clinically indicated in the opinion of the investigator (eg, because of known recent exposure), then subject has negative test for hepatitis B, hepatitis C, and/or human immunodeficiency virus (HIV).
- •For female subjects with = 4 weeks between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008: Subject has a negative urine pregnancy test at baseline prior to the first dose of AMG 827 in the open-label extension (except those at least 2 years post menopausal or surgically sterile).
- •For female subjects with > 4 weeks between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008: Subject has a negative serum pregnancy test within 28 days before initiating AMG 827 and a negative urine pregnancy test at baseline prior to the first dose of AMG 827 in the open-label extension (except those at least 2 years post menopausal or surgically sterile).
- •For subjects with = 3 months between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008, if clinically indicated in the opinion of the investigator (eg, because of known recent exposure):
- •- If the subject entered 20090072 with a negative purified protein derivative (PPD) test: Subject must have a negative PPD test within 30 days prior to the planned first dose of AMG 827. Tuberculin skin tests should be considered positive when they have greater than or equal to 5 mm of induration at 48-72 hours after test is placed.
- •- If the subject entered 20090072 with a positive PPD: Subject must have a negative Quantiferon test within 30 days prior to the planned first dose of AMG 827.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 195
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •AMG 827 specific criteria
- •Subject had any serious adverse event reported during study 20090072 and considered to be related to investigational product.
- •Subject experienced an adverse event or laboratory abnormality in study 20090072 that, in the opinion of the investigator, could cause extension of treatment to be detrimental to the subject, prevent the subject from completing the study, or interfere with the interpretation of the study results.
- •Subject has known sensitivity to any of the products to be administered during dosing. Other medical conditions
- •Subject is currently experiencing an infection of Common Terminology Criteria for Adverse Events grade 2 (if requiring oral medication) or higher. Subject is ineligible until the infection resolves.
- •Subject has a serious infection, defined as requiring hospitalization or intravenous antibiotics, within 8 weeks before the first dose of AMG 827 in 20100008.
- •For subjects with = 3 months between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008: Subject has recurrent or chronic infections, defined as = 3 infections requiring anti-microbials over the past 12 months prior to screening.
- •Subject has a significant concurrent medical condition, including
- •- Type 1 diabetes
- •- Uncontrolled type 2 diabetes
- •- Moderate to severe heart failure (New York Heart Association class III or IV)
- •- Myocardial infarction within the last year
- •- Current or history of unstable angina pectoris within the last year
- •- Uncontrolled hypertension as defined by resting blood pressure = 150/90 mmHg prior to first investigational product dose (confirmed by a repeat assessment)
- •- Severe chronic pulmonary disease (eg, requiring oxygen therapy)
- •- Major chronic inflammatory disease or connective tissue disease other than Crohn’s disease (eg, systemic lupus erythematosus, rheumatoid arthritis, psoriasis)
- •- Active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma
- •- History of cancer (except successfully treated in situ cervical cancer or squamous or basal cell carcinoma of the skin).
- •- Any condition that, in the opinion of the investigator, might cause this study to be detrimental to the subject Laboratory abnormalities
- •For subjects with > 4 weeks between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008, subject has laboratory abnormalities at screening, including
- •- Elevated aspartate aminotransferase or alanine aminotransferase (> 2x upper limit of normal)
- •- Serum direct bilirubin = 1.5x upper limit of normal
- •- Hemoglobin < 10 g/dL
- •- Hemoglobin A1c > 8.0 (for subjects with type 2 diabetes)
- •- Platelet count < 125,000 /mm3
- •- White blood cell count < 3,000 cells/mm3 - Absolute neutrophil count < 2,000/mm3 - Creatinine clearance < 50 mL/min (Cockroft-Gault formula, central lab will calculate value and provide to sites)
- •- Any other laboratory abnormality, which, in the opinion of the investigator, could cause extension of treatment to be detrimental to the subject, prevent the subject from completing the study, or interfere with the interpretation of the study results Washouts and non-permitted drugs
- •Subject has used Tysabri (natalizumab) subsequent to study 20090072. • Subject received an anti-tumor necrosis factor agent within 8 weeks prior to the first dose of AMG 8
研究者
相似试验
进行中（未招募）
不适用
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s DiseaseCrohns DiseaseMedDRA version: 12.1Level: LLTClassification code 10013099Term: Disease CrohnsEUCTR2010-020881-53-NLAmgen Inc195
已完成
2 期
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's DiseaseNL-OMON36733Amgen25
已完成
Unknown
Evaluation of long-term safety and efficacy after neuroprotective gene therapy with SIV-hPEDF for retinitis pigmentosaRetinitis PigmentosaJPRN-UMIN000049825Kyushu University10
进行中（未招募）
不适用
A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Rheumatoid Arthritis.Rheumatoid arthritisEUCTR2009-016119-38-PLAmgen Inc220
进行中（未招募）
不适用
Safety and Efficacy of AMG 827 in Subjects With RAMedDRA version: 13.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2009-016119-38-GBAmgen Inc220